WO2015121649A1 - Pharmaceutical composition comprising vemurafenib - Google Patents

Pharmaceutical composition comprising vemurafenib Download PDF

Info

Publication number
WO2015121649A1
WO2015121649A1 PCT/GB2015/050384 GB2015050384W WO2015121649A1 WO 2015121649 A1 WO2015121649 A1 WO 2015121649A1 GB 2015050384 W GB2015050384 W GB 2015050384W WO 2015121649 A1 WO2015121649 A1 WO 2015121649A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
vemurafenib
tablet
agents
Prior art date
Application number
PCT/GB2015/050384
Other languages
English (en)
French (fr)
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Limited
COTTRILL, Emily
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, COTTRILL, Emily filed Critical Cipla Limited
Publication of WO2015121649A1 publication Critical patent/WO2015121649A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor, a process for preparing such pharmaceutical compositions and use of the said pharmaceutical compositions for the treatment of cancer more specifically melanoma.
  • Melanoma is an aggressive type of skin cancer that carries significant morbidity and mortality. It was estimated that more than 68,000 Americans were diagnosed with melanoma in 2010. This number was up from the 54,200 new cases of melanoma expected in 2003.
  • Primary melanoma is a malignant neoplasm of neural crest-derived melanocytes, specialized pigmented cells predominately found in the basal layer of the epidermis.
  • the normal function of melanocytes is to produce and transfer a dark pigment called melanin to mitotically active keratinocytes, which are also found in the epidermis. The transferred melanin is concentrated in the perinuclear space of keratinocytes and protects the nucleus from UV radiation damage.
  • melanocytes to tumor cells occurs in both genetically normal and predisposed patients.
  • melanoma pathogenesis is complex and not completely understood, it likely involves interactions between environmental factors, accumulation of sequential genetic alterations, activation of oncogenes, inactivation of tumor suppressor genes, and impaired DNA repair.
  • Melanoma treatment would be directed towards surgery and would be considered as a line of treatment at any stage of melanoma.
  • Other therapies considered would be the biologic therapy, targeted therapy, chemotherapy, radiation and the like. This array of therapies would be invasive and especially surgery would be beneficial in cases where the melanoma is limited and where complete resection is possible. If the melanoma is undetected in the early stages it may spread throughout the body and progress to the stage IV or metastatic melanoma.
  • Many drugs are available either alone or in combination for oral therapy or parenteral therapy in the present era for treating or controlling metastatic melanoma.
  • One amongst such drugs is Vemurafenib.
  • Vemurafenib is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • Vemurafenib is structurally represented as:
  • WO2013087546 discloses a composition comprising solid dispersion comprising a polymer, PVP or copovidone, vemurafenib and, optionally, a surfactant and/or hydroxypropyl methylcellulose-acetate succinate.
  • WO2010114928 discloses a solid dispersion comprising vemurafenib molecularly dispersed within a polymer matrix formed by an ionic polymer in its solid state.
  • WO2011057974 discloses a method of manufacturing a solid dispersion of the amorphous form of vemurafenib and HPMCAS (Hydroxypropylmethylcellulose Acetate Succinate) for the treatment of malignant melanoma.
  • HPMCAS Hydropropylmethylcellulose Acetate Succinate
  • the recommended dose of vemurafenib is 960 mg twice daily.
  • Tablets comprising 240 mg vemurafenib are sold under the trade name Zelboraf ® .
  • the required dosage is comprised in four Zelboraf ® tablets that have to be administered orally twice a day.
  • vemurafenib may be hampered by factors such as emesis and ingestion and would ultimately lead to decreased bioavailability of vemurafenib.
  • the object of the present invention is to provide a pharmaceutical composition comprising vemurafenib and one or more pharmaceutically acceptable excipients.
  • Another object of the present invention is to provide a pharmaceutical composition comprising vemurafenib which ensure patient compliance.
  • Another object of the present invention is to provide the use of pharmaceutical composition comprising vemurafenib for the treatment of melanoma.
  • a pharmaceutical composition comprising vemurafenib and one or more pharmaceutically acceptable excipients.
  • a process for preparing a pharmaceutical composition comprising vemurafenib with at least one or more pharmaceutically acceptable excipients.
  • a method of treating unresectable or metastatic melanoma by administering a therapeutically effective amount of a pharmaceutical composition comprising vemurafenib and one or more pharmaceutically acceptable excipients to a patient in need thereof.
  • Vemurafenib is commercially available as a conventional film coated tablet formulation for the treatment of unresectable or metastatic melanoma with BRAF Y600E mutation.
  • the required dosage is comprised in four vemurafenib tablets that have to be administered orally twice a day.
  • cancer patients are usually on a multiple drug regimen demanding the administration of large numbers of tablets or capsules often along with intravenous therapy.
  • Patient compliance in such a regimen can be addressed by decreasing the number of tablets or capsules administered as well as the type of dosage forms that are administered, with due consideration to the bioavailability of the administered drug .
  • the bioavailability of the drug cannot be compromised to meet patient compliance.
  • vemurafenib as an active pharmaceutical agent used for treating melanoma, would be, preferred in a low dose oral composition provided in such dosage forms which exhibit desired therapeutic effect and at the same time would ensure patient compliance.
  • a low dose orally dispersible composition of vemurafenib when designed was considered as the best approach, as these compositions could be dispersed in water and then easily administered to the patient and thus be advantageous for use in elder and noncompliant cancer patients.
  • the present invention provides a pharmaceutical composition comprising vemurafenib which would ensure patient compliance due to simplification of therapy, ease of administration, an acceptable dosing regimen and bioavailability.
  • vemurafenib is used in broad sense to include not only “vemurafenib” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • low dose refers to a therapeutically effective dose of vemurafenib, which dose is less than the usual or the conventional dose required to produce equal or higher therapeutic effect.
  • pharmaceutical composition includes tablets, coated tablet, powder, powder for reconstitution, pellets, beads, mini-tablets, multilayer tablet, bilayered tablet, tablet-in-tablet, pills, micro-pellets, small tablet units, MUPS (multiple unit pellet system), disintegrating tablets, dispersible tablets, granules, microspheres, multiparticulates, capsule (filled with powder, powder for reconstitution, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, orally disintegrating MUPS, disintegrating tablets, dispersible tablets, granules, sprinkles, microspheres and multiparticulates), sachets (filled with powders, powders for reconstitution, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS (multiple unit pellet system), disintegrating tablets,
  • oral liquid dosage forms liquids, liquid dispersions, suspensions, solutions, emulsions, syrups, elixirs
  • oral liquid dosage forms liquids, liquid dispersions, suspensions, solutions, emulsions, syrups, elixirs
  • the pharmaceutical composition is in an oral dosage form, preferably the oral dosage form is a single unit dosage form, preferably the composition is a solid oral dosage form and preferably the single unit dosage form is for adapted once or twice a day administration.
  • the pharmaceutical composition of the present invention comprising vemurafenib is in form of an oral tablet.
  • the pharmaceutical composition comprising vemurafenib is presented in a tablet dosage form, more preferably as dispersible, disintegrating or coated tablets.
  • a pharmaceutical compositions comprising vemurafenib with one or more pharmaceutically acceptable excipients wherein the composition comprises less than 1920 mg of vemurafenib or wherein the composition is formulated to provide a total daily dose of less than 1920 mg of vemurafenib.
  • the pharmaceutical composition, according to the present invention may be administered at least once or twice a day.
  • the pharmaceutical compositions are administered once or twice a day in a dose which is less than the conventionally administered dose, which is from about 100 mg to about 1500 mg of vemurafenib, preferably from about 150 mg to about 1000 mg, preferably from about 200 mg to about 900 mg, most preferably from about 300 mg to about 800 mg of vemurafenib.
  • the pharmaceutical composition comprising vemurafenib, according to the present invention is presented in a tablet dosage form, more preferably as dispersible, disintegrating or coated tablets.
  • the inventors of the present invention have also further observed that the solubility properties of vemurafenib improved by nanosizing thus leading to better bioavailability of the drug as well as reducing the dose of the drug.
  • Nanonization of hydrophobic or poorly water-soluble drugs generally involves the production of drug nanocrystals through either chemical precipitation (bottom-up technology) or disintegration (top-down technology). Different methods may be utilized to reduce the particle size of the hydrophobic or poorly water soluble drugs. [Huabing Chen et al, discusses the various methods to develop nanoformulations in "Nanonization strategies for poorly water-soluble drugs," Drug Discovery Today, Apr 2011; 16(7-8):354-60.
  • the present invention thus provides a pharmaceutical composition
  • a pharmaceutical composition comprising vemurafenib wherein the vemurafenib is in the form of particles, wherein substantially all the particles are nanosized.
  • nanosize refers to vemurafenib particles having an average particle size of less than 2000 nm, preferably less than 1000 nm.
  • vemurafenib varies with D 90 not less than 700 nm, preferably less than 300 nm.
  • particles refers to individual particle of vemurafenib, or particles of vemurafenib granules and/or mixtures thereof.
  • the nanosize particles of the present invention can be obtained by any of the process such as but not limited to milling, precipitation, homogenization, high pressure homogenization, spray-freeze drying, supercritical fluid technology, double emulsion/solvent evaporation, PRINT (Particle replication in non-wetting templates), thermal condensation, ultrasonication, spray drying or the like. Such nanoparticles obtained by any of these processes may further be formulated into desired dosage forms.
  • the nanoparticles of the present invention may be prepared by (1) homogenizing vemurafenib and at least one excipient to produce a homogenized dispersion;
  • Suitable excipients may be used for formulating the dosage form according to the present invention such as, but not limited to, disintegrants, diluents, plasticizers, binders, glidants, lubricants, sweeteners, flavoring agents, anti-caking agents, anti-microbial agents, antifoaming agents, emulsifiers, surfactants, buffering agents and coloring agents and the like or mixtures thereof.
  • Suitable carriers, diluents or fillers for use, in the pharmaceutical compositions of the present invention may comprise one or more, but not limited to lactose (for example, spray-dried lactose, a-lactose, ⁇ -lactose) lactose available under the trade mark Tablettose, various grades of lactose available under the trade mark Pharmatose or other commercially available forms of lactose, lactitol, saccharose, sorbitol, mannitol, dextrates, dextrins, dextrose, maltodextrin, croscarmellose sodium, microcrystalline cellulose (for example, microcrystalline cellulose available under the trade mark Avicel), silicified microcrystalline cellulose, hydroxypropylcellulose, L-hydroxypropylcellulose (low substituted), hydroxypropyl methylcellulose (HPMC) or hypromellose, hydroxypropyl methylcellulose acetate succinate (HPMCAS) or hypromellosea
  • Suitable disintegrants or super disintegrants include, but are not limited to, agar-agar, calcium carbonate, crystalline cellulose, crospovidone, povidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays, alginic acid, alginates such as sodium alginate other algins, other celluloses, gums, ion-exchange resins, magnesium aluminum silicate, sodium dodecyl sulfate, sodium carboxymethyl cellulose, croscarmellose sodium, cross-linked PVP, carboxymethyl cellulose calcium, crosslinked sodium carboxymethyl cellulose, docusate sodium, guar gum, low- substituted HPC, polacrilin potassium, poloxamer, povidone, sodium glycine carbonate and sodium lauryl sulfate and the like or combinations thereof.
  • the amount of disintegrant in the pharmaceutical compositions range from about 1% to about 30%, of
  • Suitable binders may also be present in the pharmaceutical compositions of the present invention, which may comprise one or more, but not limited to polyvinyl pyrrolidone (also known as povidone), polyethylene glycol(s), acacia, alginic acid, agar, calcium carragenan, cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, dextrin, gelatin, gum arabic, guar gum, tragacanth, sodium alginate and the like or mixtures thereof.
  • polyvinyl pyrrolidone also known as povidone
  • polyethylene glycol(s) polyethylene glycol(s)
  • acacia alginic acid
  • agar calcium carragenan
  • cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose,
  • the amount of binder in the pharmaceutical compositions range from about 5% w/w to about 20 % w/w, of the total weight of the composition.
  • Glidants, anti-adherents and lubricants may also be incorporated in the pharmaceutical compositions of the present invention, which may comprise one or more, but not limited to stearic acid and pharmaceutically acceptable salts or esters thereof (for example, magnesium stearate, calcium stearate, zinc stearate, sodium stearylfumarate or other metallic stearate), talc, croscarmellose sodium, waxes (for example, microcrystalline waxes) and glycerides, mineral oil, light mineral oil, PEG, silica acid or a derivative or salt thereof (for example, silicates, silicon dioxide, colloidal silicon dioxide and polymers thereof, crospovidone, magnesium aluminosilicate and/ or magnesium aluminometasilicate), microcrystalline cellulose (for example, microcrystalline cellulose available under the trade mark Avicel), silicified microcrystalline cellulose, sucrose ester of fatty acids, hydrogenated vegetable oils (for example, hydrogenated castor oil, peanut oil, cottons
  • the amount of glidants, anti-adherents and lubricants in the pharmaceutical compositions range from about 0.1 % w/w to about 5% w/w, of the total weight of the composition.
  • Suitable solvents may also be incorporated in the pharmaceutical compositions of the present invention, which may comprise one or more, but not limited to acetone, methanol, ethanol, dimethylacetamide, dimethylformamide, dimethyl sulfoxide (DMSO), N-methyl pyrrolidone and the like or combinations thereof.
  • Suitable anti-caking additives include, but are not limited to, calcium silicate, magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc and the like or combinations thereof.
  • Suitable anti-microbial agents or preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, butyl paraben, cetylpyridinium chloride, cresol, chlorobutanol, dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethyl alcohol, phenoxyethanol, phenylmercuric acetate, phenylmercuric nitrate, potassium sorbate, propylparaben, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, thimersol, thymo, and
  • Suitable sweetening agent or taste-masking agents include, but are not limited to, essential oils, water soluble extracts, sugar (natural or synthetic), monosaccharides, oligosaccharides, aldose, ketose, dextrose, maltose, lactose, glucose, fructose, sucrose, mannitol xylitol, D- sorbitol, erythritol, pentitol, hexitol, malitol, acesulfame potassium, talin, glycyrrhizin, sucralose, aspartame, saccharin, sodium saccharin, acesulfame, thaumatin, dihydrochalcone, alitame, miraculin, monellin, stevsidesodium cyclamate, eugenylformate aldehyde flavorings and the like or combinations thereof.
  • Suitable flavors include, but are not limited to, essential oils including distillations, solvent extractions, or cold expressions of chopped flowers, leaves, peel or pulped whole fruit containing mixtures of alcohols, esters, aldehydes and lactones; essences including either diluted solutions of essential oils, or mixtures of synthetic chemicals blended to match the natural flavor of the fruit (e.g., strawberry, raspberry and black currant); artificial and natural flavors of brews and liquors, e.g., cognac, whisky, rum, gin, sherry, port, and wine; tobacco, coffee, tea, cocoa, and mint; fruit juices including expelled juice from washed, scrubbed fruits such as lemon, orange, and lime; spear mint, pepper mint, wintergreen, cinnamon, cacoe/cocoa, vanilla, liquorice, menthol, eucalyptus, aniseeds nuts (e.g., peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts), almonds, raisins; and powder,
  • Suitable antioxidants include, but are not limited to, tocopherols, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylatedhydroxyanisole, edetic acid, and edetate salts, and the like or combinations thereof.
  • Suitable texture enhancers include, but are not limited to, pectin, polyethylene oxide, and carrageenan, and the like or combinations thereof.
  • Surface stabilizers are surfactants that are capable of stabilizing the increased surfaced charge drug. Suitable amphoteric, non-ionic, cationic or anionic surfactants may be included in the pharmaceutical compositions of the present invention.
  • surfactants may comprise of one or more, but not limited to Polysorbates, Sodium dodecyl sulfate (sodium lauryl sulfate), Lauryl dimethyl amine oxide, Docusate sodium, Cetyltrimethyl ammonium bromide (CTAB) Polyethoxylated alcohols, Polyoxyethylenesorbitan, Octoxynol, N, N- dimethyldodecylamine-N-oxide, Hexadecyltrimethylammonium bromide, Polyoxyl 10 lauryl ether, Brij, Bile salts (sodium deoxycholate, sodium cholate), Polyoxyl castor oil, Nonylphenolethoxylate Cyclodextrins, Lecithin, Methylbenzethonium chloride.
  • CTAB Cetyltrimethyl ammonium bromide
  • Carboxylates Sulphonates, Petroleum sulphonates, alkylbenzenesulphonates, Naphthalenesulphonates, Olefin sulphonates, Alkyl sulphates, Sulphates, Sulphated natural oils & fats, Sulphated esters, Sulphatedalkanolamides, Alkylphenols, ethoxylated & sulphated, Ethoxylated aliphatic alcohol, polyoxy ethylene surfactants, carboxylic esters Polyethylene glycol esters, Anhydrosorbitol ester & its ethoxylated derivatives, Glycol esters of fatty acids, Carboxylic amides, Monoalkanolamine condensates, Polyoxyethylene fatty acid amides, Quaternary ammonium salts, Amines with amide linkages, Polyoxyethylene alkyl & alicyclic amines, ⁇ , ⁇ , ⁇ , ⁇ tetrakis substituted ethylenediamines 2- alky
  • the amount of the one or more surfactants in the pharmaceutical compositions range from about 2 % w/w to about 10 % w/w, of the total weight of the composition.
  • Viscosity modifying agents are excipients that are capable of stabilizing the formulation by increasing the viscosity of the formulation and thus preventing physical interaction of nanoparticles under the operating conditions employed.
  • viscosity modifying agents may comprise one or more, but not limited to derivatives of sugars, such as lactose, sucrose, saccharose, hydrolyzed starch (maltodextrin) and the like or mixtures thereof.
  • the amount of viscosity modifying agents in the one or more pharmaceutical compositions range from about 4 % w/w to about 20 % w/w, of the total weight of the composition.
  • Polymers or polymers blends may comprise one or more hydrophilic polymers, but not limited to cellulose derivates like hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate succinate, methylcellulose polymers hydroxyethylcellulose, sodium carboxymethylcellulose, carboxy methylene and carboxymethylhydroxyethylcellulose; acrylics like acrylic acid, acrylamide, and maleic anhydride polymers, acacia, gum tragacanth, locust bean gum, guar gum, or karaya gum, agar, pectin, carrageenan, gelatin, casein, zein and alginates, carboxypolymethylene, bentonite, magnesium aluminum silicate, polysaccharides, modified starch derivatives, copolymers and the like or mixtures thereof.
  • hydrophilic polymers but not limited to cellulose derivates like hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxyprop
  • the amount of the one or more polymers or polymers blends in the pharmaceutical compositions range from about 2 % w/w to about 15 % w/w of the total weight of the composition.
  • Suitable channeling agents for use in pharmaceutical compositions of the present invention may comprise one or more, but are not limited to sodium chloride, sugars, polyols and the like or mixtures thereof.
  • the amount of channeling agents in the pharmaceutical compositions range from about 0.5% to about 10% w/w of the total weight of the composition.
  • compositions may also optionally be coated, but not limited to seal coating, enteric coating, film coating or a combination thereof.
  • the pharmaceutical compositions may be film coated, seal coated or enteric coated with, but not limited to, colour mix systems (such as Opadrycolour mix systems), Aqueous Acrylic Enteric Coating System (such as Acryl-EZE ® ) and Kollicoat ® Protect.
  • the pharmaceutical composition may be enteric coated.
  • the amount of enteric coating system in the pharmaceutical compositions range from about 2 % w/w to about 15 % w/w, of the total weight of the composition.
  • the seal coat comprises film forming polymeric materials, such as but not limited to, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, methylcellulose, carboxymethylcellulose, hypromellose, acacia, gelatin and the like to increase adherence and coherence of the seal coat.
  • the amount of seal coating system in the pharmaceutical compositions range from about 1 % w/w to about 4 % w/w of the total weight of the composition.
  • pharmaceutically acceptable opacifier for use in the pharmaceutical compositions of the present invention may comprise one or more, but is not limited to titanium dioxide.
  • the pharmaceutical composition comprises vemurafenib in combination with pharmaceutical excipients comprising carriers, diluents or fillers; disintegrants; binders; glidants, lubricants or anti-adherents.
  • the pharmaceutical composition comprises vemurafenib in combination with lactose, croscarmellose sodium, hydroxyl propyl cellulose, purified water, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
  • the pharmaceutical composition comprises vemurafenib in combination with sodium lauryl sulphate, hypromellose, docusate sodium, lactose monohydrate, purified water, crospovidone, sodium chloride, silicified microcrystalline cellulose, magnesium stearate and an Aqueous Acrylic Enteric Coating System.
  • the pharmaceutical composition further comprises hypromellose acetate succinate.
  • the present invention also provides a method of treating unresectable or metastatic melanoma by administering a pharmaceutical compositions comprising vemurafenib.
  • the present invention also provides the use of the pharmaceutical compositions comprising vemurafenib for treating unresectable or metastatic melanoma.
  • the pharmaceutical compositions of the present invention may further comprise at least one additional active ingredient such as, but not limited to, MEK inhibitor, ERK inhibitor, phosphoinositide 3-kinase inhibitor, topoisomerase inhibitor, PDK inhibitor, OXPHOS inhibitors, mitochondrial inhibitors, c-KIT inhibitors, EGFR inhibitor, anti-CTLA4 antibody, DLL4 antagonist, anti-HMW-MAA antibody, peginterferon alfa-2a, dihydroorotate dehydrogenase inhibitor, AKT inhibitor compounds, proteins, synthetic proteins, antibodies, MDM2 inhibitors, cardiac glycosides, histone deacetylase inhibitor, tyrosine kinase inhibitor, inhibitor of CDK4, PDK beta inhibitor, MAPK pathway inhibitor, interleukin-2, c-Met antagonists, Hsp90 inhibitors, Wnt pathway inhibitor
  • the pharmaceutical compositions of the present invention may comprise at least one additional active ingredient such as, but not limited to, cetuximab, erlotinib, tremelimumab, lenvatinib, sorafenib, dideoxyinosine, tigecycline, bafetinib, stavudine, crizotinib, tivantinib, onartuzumab, selumetinib, irinotecan, ipilimumab, masitinib, cobimetinib and the like or combinations thereof.
  • additional active ingredient such as, but not limited to, cetuximab, erlotinib, tremelimumab, lenvatinib, sorafenib, dideoxyinosine, tigecycline, bafetinib, stavudine, crizotinib, tivantinib, onartuzumab, selumetinib, i
  • step (1) Vemurafenib, lactose and croscarmellose sodium were added and mixed. 2) The mixture obtained in step (1) was granulated with the binder solution obtained by dissolving hydroxy propyl cellulose in water.
  • step (2) The granules obtained in step (2) were dried, blended and lubricated using microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.
  • step (3) The lubricated granules obtained in step (3) were compressed to form dispersible tablets.
  • Vemurafenib, lactose and croscarmellose sodium were added and mixed.
  • step (2) The mixture obtained in step (1) was granulated with the binder solution by dissolving hydroxy propyl cellulose in water.
  • step (2) The granules obtained in step (2) were dried, blended and lubricated using microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.
  • Vemurafenib was dispersed in the solution obtained in step (1) and then milled to form a slurry.
  • step (3) The granules obtained in step (3) were dried and blended with crospovidone, silicified microcrystalline cellulose, sodium chloride and lubricated with magnesium stearate.
  • step (4) The lubricated granules obtained in step (4) were compressed to form tablets and were coated.
  • Vemurafenib was dispersed in the solution obtained in step (1) and then milled to form a slurry.
  • step (2) The slurry obtained in step (2) was sprayed onto lactose and crospovidone and granulated.
  • step (3) The granules obtained in step (3) were dried, blended with crospovidone, silicified microcrystalline cellulose, sodium chloride and lubricated with magnesium stearate
  • step (4) The lubricated granules obtained in step (4) were compressed to form tablets and were coated.
  • Crospovidone 10.0 Silicified Microcrystalline Cellulose 59.2
  • Vemurafenib was dispersed in the solution obtained in step (1) and then milled to form a slurry.
  • step (2) The slurry obtained in step (2) was sprayed onto lactose, hypromellose acetate succinate and crospovidone and granulated.
  • step (3) The granules obtained in step (3) were dried, blended with crospovidone, silicified microcrystalline cellulose, sodium chloride and lubricated with magnesium stearate.
  • step (4) The lubricated granules obtained in step (4) were compressed to form dispersible tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/GB2015/050384 2014-02-12 2015-02-12 Pharmaceutical composition comprising vemurafenib WO2015121649A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN495/MUM/2014 2014-02-12
IN495MU2014 IN2014MU00495A (enrdf_load_stackoverflow) 2014-02-12 2015-02-12

Publications (1)

Publication Number Publication Date
WO2015121649A1 true WO2015121649A1 (en) 2015-08-20

Family

ID=52544516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2015/050384 WO2015121649A1 (en) 2014-02-12 2015-02-12 Pharmaceutical composition comprising vemurafenib

Country Status (3)

Country Link
IN (1) IN2014MU00495A (enrdf_load_stackoverflow)
WO (1) WO2015121649A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500995B (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11504333B2 (en) * 2017-07-05 2022-11-22 Novartis Ag Pharmaceutical composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
WO2013087546A1 (en) * 2011-12-13 2013-06-20 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
US20100310659A1 (en) * 2009-04-03 2010-12-09 Plexxikon, Inc. Compositions and Uses Thereof
US20110112136A1 (en) * 2009-11-11 2011-05-12 Ralph Diodone Novel process for the manufacture of pharmaceutical preparations
WO2013087546A1 (en) * 2011-12-13 2013-06-20 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PNEUMOVAX 23 safely and effectively. See full prescribing information for PNEUMOVAX 23. PNEUMOVAX 23 (pneumococcal vaccine polyvalent) Sterile, Liquid Vaccine for Intramuscular or Subcutaneous In", 1 January 2011 (2011-01-01), XP055163882, Retrieved from the Internet <URL:http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf> [retrieved on 20150121] *
FLAHERTY ET AL: "Inhibition of mutated, activated BRAF in metastatic malignant melanoma", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 363, 1 January 2010 (2010-01-01), pages 809 - 819, XP009183149, ISSN: 0028-4793 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11504333B2 (en) * 2017-07-05 2022-11-22 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
IN2014MU00495A (enrdf_load_stackoverflow) 2015-09-25
ZA201500995B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
WO2015114314A1 (en) Pharmaceutical composition comprising abiraterone
US12171768B2 (en) IRAK4 degraders and uses thereof
JP4544863B2 (ja) 水溶性セルロース誘導体を含むイレッサの医薬製剤
EP2548556B1 (en) Method for improving dissolvability of anticoagulant
NO332844B1 (no) Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens, anvendelse derav og fremgangsmåte for fremstilling av det samme.
WO2015071668A1 (en) Pharmaceutical compositions
WO2015145145A1 (en) Pharmaceutical composition comprising lapatinib
US20120114711A1 (en) Pharmaceutical composition having improved solubility
JP2009215293A (ja) 食物なしでジプラシドンを投与するための方法、剤形、およびキット
JPWO2018190294A1 (ja) エスシタロプラム医薬組成物
CN112236146A (zh) 稳定性优良的固体制剂
CA2860098A1 (en) Immediate release multi unit pellet system
WO2015145157A1 (en) Pharmaceutical composition comprising pazopanib
CN107613978B (zh) Mek抑制剂的药物组合物及其制备方法
EP3718548B1 (en) Solid dispersion
WO2015140569A1 (en) Pharmaceutical composition
WO2015136294A1 (en) Pharmaceutical composittion comprising rilpivirine
WO2015121649A1 (en) Pharmaceutical composition comprising vemurafenib
US9248102B2 (en) Tablet containing 5-hydroxy-1H-imidazole-4-carboxamide
SG190326A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
EP3981469B1 (en) Therapeutic for gout or hyperuricemia
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
JP2008094751A (ja) プランルカスト水和物含有医薬組成物
WO2016070696A1 (zh) 达比加群酯或其盐的投药制剂及其制备方法
WO2020048449A1 (zh) 包含1,3,5-三嗪衍生物或其盐的固体药物组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15705694

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15705694

Country of ref document: EP

Kind code of ref document: A1